Kiniksa Pharmaceuticals International, plc
Nasdaq KNSA · London, United Kingdom
Works in Cardiovascular · Infectious disease · Respiratory
Kiniksa Pharmaceuticals International, plc is a clinical trial sponsor based in London, United Kingdom, listed as Nasdaq KNSA. It has 3 active clinical trials with 945 planned participants, in Cardiovascular, Infectious disease and Respiratory. Since 2021 it has completed 1 trial and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq KNSA
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 945 planned participants, in Cardiovascular, Infectious disease, Respiratory. Since 2021 it has completed 1 trial and stopped 1 early.
Kiniksa Pharmaceuticals International, plc is based in London, United Kingdom and is listed as Nasdaq KNSA. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Kiniksa Pharmaceuticals International, plc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-30.
Approve Suite is not affiliated with Kiniksa Pharmaceuticals International, plc.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.